Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
|Slideshows|July 24, 2017
4 Neurology Apps to Empower Older Patients
Author(s)Veronica Hackethal, MD
These apps are designed to improve treatment adherence, language skills, symptom tracking, communication, and other helpful functions.
Advertisement
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
2
Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy
3
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
4
Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162
5